Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Filgotinib in RA (FINCH 2)
NCT02873936Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Jul 2016
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial of filgotinib in rheumatoid arthritis (RA) (3 arms), sponsored by Gilead Sciences. Primary endpoint: American College of Rheumatology 20% Improvement at 12 weeks. Started Jul 2016; status: completed.
02
Drugs
filgotinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02873936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02873936.